Blueprint Medicines (BPMC) Misses Q1 EPS by 16c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Blueprint Medicines (BPMC) Misses Q1 EPS by 16c

Blueprint Medicines Reports First Quarter 2018 Financial Results

May 2, 2018 7:00 AM EDT

CAMBRIDGE, Mass., May 2, 2018 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today reported financial results and provided a business update for the quarter ended March 31, 2018.

"In the first quarter, we continued to make significant progress across our portfolio toward our vision of rapidly delivering potentially transformative kinase medicines to patients with genomically... More